title: Dose Effect of Rhenium (I)-diselenoether as Anticancer Drug in Resistant Breast Tumor-bearing Mice After Repeated Administrations.
abstract: Rhenium (I)-diselenoether has shown promising antiproliferative efficacy in both in vitro and in vivo models. However, the maximal tolerated dose and dose-effect relationships have not been fully addressed for this compound. Here, we evaluated the tolerance and efficacy of three dose-levels (namely 10, 40 and 100 mg/kg) intraperitoneally administered daily over 28 days in mice bearing the resistant MDA-MB231 breast cancer cell line. The upper dose was found to be toxic and was reduced to 60 mg/kg. The 10 mg/kg dose well tolerated, whereas 40 mg/kg was associated with 10% mortality (LD10). Both 10 and 40 mg/kg dosing achieved a significantly similar regression of tumor growth compared with untreated animals. This study suggests that 10 mg/kg daily is the recommended dose for rhenium (I) diselenoether.
authors: Society for the Coordination of Research, Algajola, France philippe.collery@gmail.com.|Association of Research and Development Center for the Therapeutic Use of Organo-Metallic Compounds, Polyclinic Maymard, Bastia, France.
authors: Philippe
authors: P
authors: Collery
authors: Association of Research and Development Center for the Therapeutic Use of Organo-Metallic Compounds, Polyclinic Maymard, Bastia, France.|Laboratory of the Corsican Office of Hydraulic Equipment, Bastia, France.
authors: François
authors: F
authors: Santoni
authors: SMARTc - Simulation and Modeling: Adaptative Response for Therapeutics in Cancer, UMR INSERM 911, Faculty of Pharmacy University of Aix-Marseille, Marseille, France.
authors: Joseph
authors: J
authors: Ciccolini
authors: SMARTc - Simulation and Modeling: Adaptative Response for Therapeutics in Cancer, UMR INSERM 911, Faculty of Pharmacy University of Aix-Marseille, Marseille, France.
authors: Thi Ngoc Nga
authors: TN
authors: Tran
authors: UMR CNRS 8612, Galien Institute, Faculty of Pharmacy, University Paris-Saclay, Châtenay-Malabry, France.
authors: Ahmed
authors: A
authors: Mohsen
authors: UMR CNRS 8612, Galien Institute, Faculty of Pharmacy, University Paris-Saclay, Châtenay-Malabry, France.
authors: Didier
authors: D
authors: Desmaele
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D004986:Ether / Q000737:chemistry*; D015674:Mammary Neoplasms, Animal / Q000188:drug therapy*; D051379:Mice; D012211:Rhenium / Q000737:chemistry*; D018036:Selenium Compounds / Q000737:chemistry / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D018036:Selenium Compounds; D004986:Ether; D012211:Rhenium
keywords: MDA-MB231; Rhenium (Re); bioluminescence; breast cancer; in vivo experiment; mice; selenium (Se)